Status:
ACTIVE_NOT_RECRUITING
Duration of Protection of Nirsevimab Against Hospitalisation for Respiratory Syncytial Virus Infection
Lead Sponsor:
Griffith University
Conditions:
Respiratory Syncytial Viral (RSV) Infections
Eligibility:
All Genders
Up to 1 years
Brief Summary
Respiratory syncytial virus (RSV) is a leading cause of hospitalizations for acute lower respiratory tract infection (LRTI) in infants. In Australia approximately 1.5% of infants are hospitalized due ...
Eligibility Criteria
Inclusion
- Any infant born between 15 April 2024 and 30 April 2025 and hospitalized for any reason between 15 April 2024 and 30 April 2026.
Exclusion
- Infants who admitted to hospitals with an elective admission. ((i.e. admissions that are planned ahead of time, such as scheduled surgeries or other pre-arranged medical procedures).
Key Trial Info
Start Date :
April 15 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2027
Estimated Enrollment :
4350 Patients enrolled
Trial Details
Trial ID
NCT06993753
Start Date
April 15 2024
End Date
March 31 2027
Last Update
May 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Griffith University
Gold Coast, Queensland, Australia, 4215